PLASMAPHERESIS FOR NEPHROLOGY
https://doi.org/10.24884/1561-6274-2017-21-4-95-101
Abstract
Almost all chronic kidney disease in varying degrees, are associated with disorders of the internal environment, mainly autoimmune nature. Drug therapy is not always effective and can lead to additional disorders. Pathogenetically justified is the use of plasmapheresis.
About the Authors
V. A. Voinov
First Pavlov Saint Petersburg state medical university
Russian Federation
Russian Federation
Prof., MD, PhD, DMedSci.
Russia, 197022, Saint Petersburg, L.Tolstoy st. 6/8, build. 44, First Pavlov Saint Petersburg state medical university, Gravitation blood surgery department. Phone: (812) 338-78-07,
K. S. Karchevsky
First Pavlov Saint Petersburg state medical university
Russian Federation
Russian Federation
MD
197022, Russia, Saint Petersburg, L.Tolstoy st. 6/8, build. 44, First Pavlov Saint Petersburg state medical university, Gravitation blood surgery department. Phone: (812) 338-78-07
O. V. Isaulov
First Pavlov Saint Petersburg state medical university
Russian Federation
Russian Federation
MD
197022, Russia, Saint Petersburg, L.Tolstoy st. 6/8, build. 44, First Pavlov Saint Petersburg state medical university, Gravitation blood surgery department. Phone: (812) 338-78-07
References
1. Chandnani HK, Jain R, Patamasucon P. Group C streptococcus causing rheumatic heart disease in a child. J Emerg Med 2015; 49 (1): 12-14
2. Chen KR, Carlson JA. Clinical approach to cutaneous vasculitis. Am J Clin Dermatol 2008; 9 (2): 71-92
3. Fisher A. Die Wandlung der postinfektiösen Glomerulonephritis. Ther Umsch 2015; 72 (3): 141-147
4. Haris A, Arányi J, Braunitzer H et al. Role of plasmapheresis in immunological kidney diseases. Experience from 1050 completed plasmapheresis treatment sessions. Orv Hetil 2011; 152 (28): 1110-1119
5. Baweja S, Wiggins K, Lee D et al. Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach. J Artif Organs 2011; 14(1): 9-22
6. Walsh M, Catapano F, Szpirt W et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: meta-analysis. Am J Kidney Dis 2011; 57 (4): 566-574
7. Zhang YY, Tang Z, Chen DM et al. Comparison of double filtration plasmapheresis with immunoadsorbtion therapy in patients with anti-glomerular basement membrane nephritis. BMC Nephrol 2014; 15: 128
8. Masmoudi A, Hajiaji Darouiche M, Ben Salah H et al. Cutaneous abnormalities in patients with end stage renal failure on chronic hemodialysis. A study of 458 patients. J Dermatol Case Rep 2014; 8 (4): 86-94
9. Inui S. Nalfurafine hydrochloride to treat pruritus: a review. Clin Cosmet Investig Dermatol 2015; 11 (8): 249-255
10. Moledina DG, Perry Wilson F. Pharmacologic treatment of common symptoms in dialysis patients: a narrative review. Semin Dial 2015; 28 (4): 377-383
11. Fuhrmann V, Drilz A, Trauner M. Extracorporeal artificial liver support systems in the management of intractable cholestatic pruritus. Liver Int 2011; 31 (Suppl. 3): 31-33
12. Петрова ВИ, Джулакян УЛ, Фёдорова ЛН и др. Эффективный плазмаферез у больной с анемией хронических заболеваний. Материалы XХ конференции московского общества гемафереза. Дубна, 2012; 102-103 [Petrova VI, Djulakyan UL, Fedorova LN. Effektivnyi plasmaferes u bol’noi s anemiei khronicheskih zabolevanii. Materialy XX konferencii moskovskogo obshestva gemaferesa. Dubna, 2012; 102-103]
13. Loo CY, Mohamed Said MS, Mohd R et al. Immunoadsorption and plasmapheresis are equally efficacious as adjunctive therapies for severe lupus nephritis. Transfus Apher Sci 2010; 43 (3): 335-340
14. Попов АС. Применение безаппаратного мембранного
15. плазмафереза во время ликвидации медико-санитарных последствий чрезвычайных ситуаций. Эфферентная и физико-химическая медицина 2011; (4): 27-30 [Popov AS. Primenenie bezapparatnogo membrannogo plasmaferesa vo vremya likvidacii medico-sanitarnyh posledstvii chrezvychainyh situacii. Efferentnaya I fizikihimicheskaya medicina 2011; (4): 27-30]
16. Bolton WK. Pulmonary renal syndrome and emergency therapy. Contrib Nephrol 2010; 165: 166-173
17. Villiger PM, Guillevin L. Microscopic polyangiitis: Clinical presentation. Autoimmun Rev 2010; 9 (12): 812-819
18. Balogun RA, Abdel-Rahman EM. Therapeutic plasma exchange and renal related vasculitis: therapeutic apheresis academy 2010. J Clin Apher 2011; 26 (5): P. 291-296
19. Casian A, Jayne D. Plasma exchange in the treatment of Wegener’s granulomatosis, microscopic polyangiitis, ChurgStrauss syndrome and renal limited vasculitis. Curr Opin Rheumatol 2011; 23 (1) 12-17
20. Gregersen JW., Kristensen T, Krag SR et al. Early plasma
21. exchange improves outcome in PR3-ANCA-positive renal vasculitis. Clin Exp Rheumatol 2012; 30 (1, Suppl 70): S39-47
22. Sinico RA, Di Toma L, Radice A. Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis. Autoimmun Rev 2013; 12 (4): 477-482
23. Isoda K, Nuri K, Shoda T et al. Microscopic polyangiitis complicated with cerebral infarction and hemorrhage: a case report and review of literature. Nihon Rinsho Meneki Gakkai Kaishi 2010; 33 (2): 111-115
24. Pérez-Suárez G, Marrero D, Rodríguez R et al. Goodpasture’s syndrome with neurologic involvement and negative ANCA. Nefrologia 2010; 30 (5): 584-587
25. Delogu LG, Deidda S, Delitala G, Manetti R. Infectious diseases and autoimmunity. J Infect Dev Ctries 2011; 5 (10): 679-687
26. Hajima N, Michiko A, Atsunori K et al. A case report of efficiency of double filtration plasmapheresis in treatment of Goodpasture’s syndrome. Ther Apher Dial 2009; 13 (4): 373-377
27. Thompson GR. Therapeutic apheresis in UK. Эфферентная терапия 2013; 19 (1): 35 [Efferentnaya terapiya]
28. Yamaji K, Kim YJ, Tsuda H, Takasaki Y. Long-term clinical outcomes of synchronized therapy with plasmapheresis and intravenous cyclophosphamide pulse therapy in the treatment of steroidresistant lupus nephritis. Ther Apher Dial 2008;12 (4): 298-305
29. Yoon KH. Efficacy and cytokine modulating effects of tacrolimus in systemic lupus erythematosus: a review. J Biomed Biotechnol 2010: 686480
30. Hesselink DA, Bouamar R, van Gelder T. The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity. Ther Drug Monit 2010; 32 (4): 387-393
31. Pietrogrande M, De Vita S, Zignego AL et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011;10 (8): 444-454
32. Ramunni A, Lauletta G, Brascia P et al. Double-filtration plasmapheresis in the treatment of leg ulcers in cryoglobulinemia. J Clin Apher 2008; 23 (3) 118-122
33. Ansell SM, Kyle RA, Reeder CB et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc 2010; 85 (9): 824-83
34. Stone MJ. Waldenström’s macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia. Clin Lymphoma Myeloma 2009; 9 (1): 97-99.
35. Варламова СВ, Волкова ЛМ, Петрова ВИ и др. Особенности лечебного гемафереза в гематологической клинике. Эфферентная терапия 2013;19 (1): 76 [Varlamova SV, Volkova LM, Petrova VI i dr. Osobennosti lechebnogo gemaferesa v gematolochiskoi praktike. Efferentnaya terapiya 2013; 19 (1): 76
36. Kleeberg L, Morgera S, Jacob C et al. Novel renal replacement strategies for the elimination of serum free light chains in patients with kappa light chain nepfropaty. Eur J Med Res 2009; 14 (2): 47-54
37. Gupta D, Bachegowda L, Phadke G et al. Role of plasmapheresis in the management of myeloma kidney: a systematic review. Hemodial Int 2010; 14 (4): 355-363
38. Ciccarelli BT, Yang G, Hatjiharissi E et al. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma 2009; 9 (1): 56-58
39. Воинов ВА. Метаболический синдром и эфферентная терапия. Научный Альманах ПСПбГМУ 2017; (8): 6-10 [Voinov VA. Metabolicheskii sindrom. Nauchnyi al’manah PSPbGMU 2017: (8): 6-10]
40. D’Agati VD, Kaskel FJ, Falk RJ et al. Focal segmental glomerulosclerosis. N Engl J Med 2011; 365; 2398-2411
41. Keith DS. Therapeutic apheresis rescue mission: recurrent focal segmental glomerulosclerosis in renal allografts. Semin Dial 2012; 25: 190-192
42. Gonzalez E, Ettenger R, Rianthavorn P. et al. Preemptive plasmapheresis and recurrence of focal segmental glomerulosclerosis in pediatric renal transplantation. Pediatr Transplant 2011;15; 495-501
43. Gungor O, Sen S, Kircelli F et al. Plasmapheresis therapy in renal transplant patients: five-year experience. Transplant Proc 2011; 43; 853-857
44. Воинов ВА. Эфферентная терапия. Мембранный плазмаферез. Эскулап, М., 2010: 40 [Voinov VA. Efferentnaya terapiya. Membranny plasmaferes. Eslulap, M., 2010: 400].
45. Соловьёв СК, Насонов ЕЛ. Новые подходы к лечению аутоиммунных ревматических заболеваний. Анти В-клеточная терапия. Вестник «МЕДСИ» 2011; 12: 5-18 [Soloviev SK, Nasonov EL. Novye podhody k lecheniu autoimmunnyh revmaticheskih zabolevanii. Anyi B-kletochnaya terapiya. Vestnik “MEDSI” 2011; 12: 5-18]
46. Ruch J, McMahon B, Ramsey G, Kwaan HC. Catastrophic multiple organ ischemia due to an anti-Pr cold agglutinin developing in a patient with mixed cryoglobulinemia after treatment with rituximab. Am J Hematol 2009; 84 (2): 120-122
47. Воинов ВА, Горбенко ПП, Фотеева ТС, Кенаров ПД. Эфферентная терапия в предупреждении преждевременного старения. Донозология и здоровый образ жизни 2015; 2: 83-87 [Voinov VA, Gorbenko PP, Foteeva TS, Kenarov PD. Efferentnaiya terapiya v preduprejdenii prejdevremennogo stareniya. Donozologiya I zdorovyi obraz zjizni 2015; 2: 83-87]
48. Voinov VA. Membrane plasmapheresis in wide range of diseases. Proc. XV ASFA and WAA Joint Conference, San-Francisco, CA, 04-04-2014. P. 32
Review
For citations:
Voinov V.A., Karchevsky K.S., Isaulov O.V. PLASMAPHERESIS FOR NEPHROLOGY. Nephrology (Saint-Petersburg). 2017;21(4):95-101. (In Russ.) https://doi.org/10.24884/1561-6274-2017-21-4-95-101
Views:
8941
Email this article 